Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Chardan Capital
Chardan Capital initiated coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report published on Wednesday, Marketbeat reports. The brokerage issued a buy rating and a $55.00 price objective on the biopharmaceutical company’s stock. A number of other analysts have also recently commented on XENE. The Goldman Sachs Group lowered their price […]
Chardan Capital initiated coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report published on Wednesday, Marketbeat reports. The brokerage issued a buy rating and a $55.00 price objective on the biopharmaceutical company’s stock. A number of other analysts have also recently commented on XENE. The Goldman Sachs Group lowered their price […]
